SCHEMBL20205975

SCHEMBL20205975

Cc1ccc(F)c(C(=O)NC2(C)CCN(S)CC2)n1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RET P07949 8/20 0.44
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
HCRTR1 O43613 1/20 0.37
HCRTR2 O43614 1/20 0.37
CCNE1 P24864 1/20 0.34
CDK2 P24941 1/20 0.34
USP30 Q70CQ3 1/20 0.34
CD38 P28907 1/20 0.34
PRKCB P05771 1/20 0.34
GPR6 P46095 1/20 0.34
CCR3 P51677 1/20 0.33
GRM5 P41594 1/20 0.33
NTRK1 P04629 2/20 0.33
JAK2 O60674 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20070355 0.90 RET (0.44) RETPDE4APDE4BPDE4CPDE4D
SCHEMBL20148013 0.87 RET (0.42) RETPDE4APDE4BPDE4CPDE4D
SCHEMBL20147640 0.86 RET (0.43) RETPDE4APDE4BPDE4CPDE4D
SCHEMBL20205829 0.77 RET (0.41) RETUSP30PRKCBCCR3
SCHEMBL20205896 0.77 PDE4A (0.37) RETPDE4APDE4BPDE4CPDE4D
SCHEMBL20069787 0.76 RET (0.43) RETPDE4APDE4BPDE4CPDE4D
SCHEMBL20068862 0.75 RET (0.46) RETPDE4APDE4BPDE4CPDE4D
SCHEMBL20205759 0.74 RET (0.41) RETUSP30CCR3
SCHEMBL20070360 0.74 RET (0.46) RETPDE4APDE4BPDE4CPDE4D
SCHEMBL20147639 0.73 RET (0.41) RETPDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 RET 1/4885PDE4A 728/4885PDE4B 715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.